Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Fauci: HIV Can Be Stopped, but Vaccine Remains Elusive

    Fauci: HIV Can Be Stopped, but Vaccine Remains Elusive

    Faint light after decades and millions of deaths

    June 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    AIDS vaccine efforts move forward, but full prevention is elusive goal

    Rare But Real Threat of Occupational HIV Remains

    Fauci says routine HIV testing critical

    Related Products

    Can Warfarin be Stopped Safely in Patients at High Risk for Stroke? | Single Article

    True simplicity remains elusive for IC forms | Single Article

    STD Quarterly: HIV vaccine update: Progress made, but more work is left to do in research | Single Article

    One of the great pandemics in human history has been fought to a near draw, with no vaccine in sight but treatments that dramatically extend life and block transmission to others.

    Twenty-five million global deaths later, there is cause for some well-earned, tempered optimism on HIV/AIDS.

    Giving this forecast considerable credibility is the man delivering it: Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases at the NIH. Fauci has been involved in HIV prevention since the virus first appeared in the U.S. in 1981.

    Almost four decades later, he is optimistic — with a quick caveat.

    “I’m somewhat reserved on how we’re going to get to the end game, but the reason for the optimism is that we now have the tools — which have been proven in a variety of clinical trial settings — that can give you the ammunition, if implemented in an aggressive and sustained way, to actually turn around the trajectory of the epidemic,” Fauci said in a recent podcast by the CDC.

    Current therapies can reduce the virus to essentially undetectable levels, he explained.

    That’s not a cure in the traditional sense, but it enables those living with HIV — once a universal death sentence — to have ever-increasing lifespans. “You can essentially save the life and prevent illness in the individual person,” he said.

    “We also know that, when you decrease the level of virus to below detectable level, it makes it virtually impossible for that person to transmit the virus to someone else. We call that ‘treatment as prevention.’”

    There are now more ways to prevent HIV in high-risk people, including pre-exposure prophylaxis (PrEP) in a single pill.

    “The efficacy of that is well over 95%,” Fauci said.

    Theoretically speaking, these medical breakthroughs mean if all the people with HIV were under treatment and all of their sex partners on PrEP, sexual transmission stops.

    The real-world problem is implementing such an approach not just in industrialized countries, but in regions with insufficient healthcare infrastructure. “You can certainly do it in select places,” Fauci said.

    “So, that’s the basis for the optimism, that it can be done. But we have an ‘implementation gap.’ We have the tools, but we really have not been able to fully implement them to the degree to get the effect that we want.”

    The holy grail of HIV research remains the creation of a vaccine. It has been elusive and remains so.

    For other infectious diseases that have highly effective vaccines — smallpox, polio, measles — natural infection generates a strong immune response in the human body, he explains.

    “That’s the fundamental basis of a ‘proof of concept’ — that a vaccine can induce a response that ultimately would be protective,” he said.

    “That’s why we were confident that sooner or later we would get vaccines for smallpox, for polio, for measles, and other pathogens. With HIV, it’s a different story.”

    For reasons that are not completely understood, the body does not have a very good natural immune response against HIV.

    “It certainly makes an immune response, but it doesn’t, on its own, suppress the virus, and it doesn’t certainly eradicate the virus,” he said.

    “When you’re making a vaccine, the best thing to do is to mimic natural infection, without hurting the patient.”

    However, efforts to mimic natural HIV infection do not generate the needed immune response to create a vaccine.

    “We have a major challenge with an HIV vaccine,” Fauci said.

    “[Which] is to make a vaccine that would be doing even better than nature could do — to induce a response that’s even better than what natural infection induces.”

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 45, No. 6) - June 2018
    June 1, 2018

    Table Of Contents

    Lightning Strikes: Fatal Infections of Rare Origin

    IC Leadership Rounds: An Idea Whose Time Has Come?

    HICPAC Taking New Approach to IC Recommendations

    Consider Probiotics in Patients at High Risk of C. diff Infection

    Fauci: HIV Can Be Stopped, but Vaccine Remains Elusive

    Flu Mandates: Consider Accommodations and Avoid a Lawsuit

    Hair Apparent: Surgeon Rebellion Succeeds on Head Covers

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing